Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1618178 | 1.00 | LMNA (0.73) | LMNAKDM4EUSP2ALDH1A1POLB | |
| SCHEMBL30760509 | 0.86 | LMNA (0.57) | LMNAKDM4EUSP2ALDH1A1POLB | |
| SCHEMBL10547816 | 0.84 | LMNA (0.55) | LMNAKDM4EUSP2ALDH1A1POLB | |
| SCHEMBL30760453 | 0.81 | LMNA (0.51) | LMNAKDM4EUSP2ALDH1A1POLB | |
| SCHEMBL11710533 | 0.81 | MEN1 (0.56) | LMNAKDM4EUSP2ALDH1A1POLB | |
| SCHEMBL5935004 | 0.81 | LMNA (0.51) | LMNAKDM4EUSP2ALDH1A1POLB | |
| SCHEMBL24793061 | 0.80 | LMNA (0.50) | LMNAKDM4EUSP2ALDH1A1POLB | |
| SCHEMBL24793060 | 0.80 | LMNA (0.50) | LMNAKDM4EUSP2ALDH1A1POLB | |
| SCHEMBL4799669 | 0.80 | ALDH1A1 (0.69) | LMNAKDM4EUSP2ALDH1A1POLB | |
| SCHEMBL4420917 | 0.79 | LMNA (0.49) | LMNAALDH1A1POLBL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117480195-A | Epoxy resin and method for producing epoxy resin | 三菱化学株式会社 | 2024-01-30 | — | — | CN | disclosed |
| WO-2013050938-A1 | 3,7-DIAZABICYCLO[3.3.1]NONANE AND 9-OXA-3,7-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-11 | — | — | WO | disclosed |
| WO-2013050938-A1 | 3,7-DIAZABICYCLO[3.3.1]NONANE AND 9-OXA-3,7-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-11 | — | — | WO | disclosed |
| US-7772229-B2 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| EP-1554285-B1 | CHEMICAL INTERMEDIATE | ASTRAZENECA AB (SE) | 2010-01-13 | — | — | EP | disclosed |
| US-20090326221-A1 | New oxabispidine compunds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB, (SE) | 2009-12-31 | — | — | US | disclosed |
| US-20090240051-A1 | New process for the production of oxabispidines | ASTRAZENECA AB (SE) | 2009-09-24 | — | — | US | disclosed |
| US-20090062532-A1 | Chemical Intermediate | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090036675-A1 | New process for production of oxabispidines | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
| US-7439355-B2 | Process for the production of oxabispidines | ASTRAZENECA AB (SE) | 2008-10-21 | — | — | US | disclosed |
| US-20030153564-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB | 2003-08-14 | — | — | US | disclosed |
| EP-1330462-A1 | NEW PROCESS FOR THE PRODUCTION OF OXABISPIDINES | AstraZeneca AB (SE) | 2003-07-30 | — | — | EP | disclosed |
| US-6559143-B1 | Class III electrophysiological activity, drugs which prolong the trans-membrane action potential duration and refractoriness, without affecting cardiac conduction | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | disclosed |
| WO-2002083691-A1 | NEW PROCESS FOR THE PREPARATION OF OXABISPIDINES | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083689-A1 | 3,7-DIAZABICYCLO [3.3.1] FORMULATIONS AS ANTI-ARRYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083688-A1 | 3,7-DIAZABICYCLO [3.3.1] FORMULATIONS AS ANTIARHYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
| EP-1235831-A2 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2002-09-04 | — | — | EP | disclosed |
| WO-2002028864-A1 | NEW PROCESS FOR THE PRODUCTION OF OXABISPIDINES | ASTRAZENECA AB (SE) | 2002-04-11 | — | — | WO | disclosed |
| WO-2001028992-A2 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2001-04-26 | — | — | WO | disclosed |
| US-4038455-A | USING N-GLYCIDYL COMPOUNDS | INVENTA AG FUR FORSCHUNG UND PATENTVERWERTUNG (CH) | 1977-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153564-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, CACNA1E, RYR1 | LMNA 1110/4885KDM4E 4163/4885USP2 4272/4885 |
| US-20090326221-A1 | New oxabispidine compunds useful in the treatment of cardiac arrhythmias | KCNH1, CACNA1E, SCN1B | LMNA 1440/4885KDM4E 3938/4885USP2 4085/4885 |
| US-20090240051-A1 | New process for the production of oxabispidines | AVPR1B, CCNB1, QDPR | LMNA 3851/4885KDM4E 4084/4885USP2 4240/4885 |
| US-20090036675-A1 | New process for production of oxabispidines | AVPR1B, CCNB1, DHPS | LMNA 3919/4885KDM4E 4446/4885USP2 4326/4885 |
| US-20090062532-A1 | Chemical Intermediate | NAT1, CYP2B6, CBR1 | LMNA 1093/4885KDM4E 3929/4885USP2 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.